ArticleCureus2025
Safety of Anesthesia With Dexmedetomidine for Muscle and Nerve Biopsy - A Review of 100 Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain during muscle and nerve biopsies is a distressing complication for patients. Dexmedetomidine, an α2-adrenoreceptor agonist, has analgesic as well as sedative effects and causes less respiratory depression. This study aimed to clarify the safety of anesthesia using dexmedetomidine for muscle and nerve biopsies. We retrospectively evaluated the safety in 100 patients who underwent anesthesia with dexmedetomidine during muscle or nerve biopsies at our institution. Adverse events were defined as follows: bradycardia as heart rate <50 bpm, hypotension as systolic blood pressure <70 mmHg, desaturation as SpO2 < or =93%, and delayed awakening as being unable to drink or eat within two hours post-operation. The major adverse events were bradycardia (20 out of 98 patients, 20%) and hypotension (six out of 100 patients, 6%); however, these adverse events did not interrupt the biopsy. There was no adverse desaturation. None of the biopsies had to be interrupted due to any other adverse event. Our findings suggest that dexmedetomidine can be safely administered for muscle and nerve biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.